title: CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
abstract: CI-924 (CI), 5,5'-[[1,1'-biphenyl]-2,5-diylbis(oxy)]bis[2,2- dimethylpentanoic acid] is chemically similar to gemfibrozil. Patients with Type II (n = 13) and Type IV (n = 22) hyperlipoproteinaemia (HLP) were maintained 12 weeks on a baseline diet containing 55% sugar, 15% protein 30% fat and less than 300 mg cholesterol daily to stabilize weight and lipids. They were then entered in a parallel group double-blinded protocol and received 0, 300, 600, or 1200 mg CI p.o. daily for 12 weeks. CI consistently elevated anti-atherogenic HDL and lowered VLDL at 600 mg/day in both Type II and Type IV HPL at 8 weeks. In Type II patients, CI lowered cholesterol, decreased LDL/HDL and increased ApoA-I. In Type IV patients, CI also lowered TC while elevating LDL and ApoA-II. CI had no effect on Apo-B, LDL-ApoB, or Apo-E.
authors.affiliation: Clinical Pharmacology Program, Oklahoma Medical Research Foundation, Oklahoma City.
authors.forename: C N
authors.initials: CN
authors.lastname: Corder
authors.forename: H U
authors.initials: HU
authors.lastname: Kloer
authors.forename: M D
authors.initials: MD
authors.lastname: Price
mesh_terms: D001053:Apolipoproteins / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D015248:Gemfibrozil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D001053:Apolipoproteins; D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; C038574:CI 924; D015248:Gemfibrozil